loading page

Is EQ-5D-Y a useful tool to assess health outcomes in children with asthma? An analysis of child and caregiver reporting.
  • +6
  • Zhou Wenjing,
  • Bo Ding,
  • Michael Herdman,
  • Zhihao Yang,
  • Bin Wu,
  • Pei Wang,
  • Jan Busschbach,
  • Yanming Lu,
  • Nan Luo
Zhou Wenjing
Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital

Corresponding Author:[email protected]

Author Profile
Bo Ding
Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital
Author Profile
Michael Herdman
Office of Health Economics
Author Profile
Zhihao Yang
Guizhou Medical University
Author Profile
Bin Wu
Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital
Author Profile
Pei Wang
Fudan University School of Public Health
Author Profile
Jan Busschbach
Erasmus MC Afdeling Psychiatrie
Author Profile
Yanming Lu
Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital
Author Profile
Nan Luo
National University Singapore Saw Swee Hock School of Public Health
Author Profile

Abstract

[Background] EQ-5D instruments (HRQOL), incuding the three-level (Y-3L) and five-level (Y-5L) child-friendly versions (EQ-5D-Y) are widely employed for assessing health-related quality of life. However, their effectiveness in children with asthma remains understudied. This study aimed to assess their performance in pediatric asthma patients and their caregivers. [Methods] Dyads of asthmatic patients (n=76, aged 8-16.7) and caregivers completed Y-5L and Y-3L, respectively, at two visits. Test-retest reliability and patient-caregiver agreement were assessed via intraclass correlation coefficient (ICC). Known-groups validity was assessed by comparing scores across varying asthma control levels. Responsiveness was assessed in children showing improved overall health and asthma control. [Results] ICCs for test-retest reliability ranged from 0.744 to 0.898 (self-complete) and 0.525 to 0.767 (proxy), indicating satisfactory reliability. As expected, overall scores for both EQ-5D-Y versions were higher (better HRQOL) in well-/partially-controlled asthma patients. Standardized effect sizes ranged from 0.19 to 1.00 (self-complete), 0.39 to 0.83 (proxy), and 0.26 to 1.40 (EQ VAS) in improved patients. Patient-caregiver agreement ranged from moderate to good. [Conclusion] Both self-complete and proxy EQ-5D-Y versions appeared to be suitable for assessing HRQOL in pediatric asthma patients, with the self-complete version being more preferable. Further investigation on the responsiveness of EQ-5D-Y is warranted.